

Haematologica
HAEMATOL/2019/223891
Version 3

An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit of intensified treatment regimens

Francesca Schieppati, Piera Balzarini, Simona Fisogni, Alessandro Re, Chiara Pagani, Nicola Bianchetti, Lorenzo Micheli, Angela Passi, Samantha Ferrari, Adriana Maifredi, Chiara Bottelli, Rossella Leopaldo, Wilma Pellegrini, Fabio Facchetti, Giuseppe Rossi, and Alessandra Tucci

Disclosures: Authors declare that there are no competing financial interests in relation to the work described, and that there are no personal relationships with people or organizations that could inappropriately bias their work. No third parties funds were issued for this study and there are no patents or copyright to declare.

Contributions: FS and PB contributed equally to this paper. FS, AT, PB and GR designed the study. FS, LM, and AP were responsible for data collection. AR, CP, NB, AP, SaFe, and CB provided patient care. PB, SiFi, and VP were responsible for laboratory investigations. FF coordinated laboratory investigations. FS conducted data analysis, and wrote the first draft of the report. FS, PB, AT, GR, and FF critically reviewed the draft. AM and RL were responsible for submission of the study to the Ethical Committee. All authors reviewed the draft and approved the final report for publication.